Benefits
Skin hydration and smoothness: topical only, no published trial
The company reports four clinical studies of Bonicel, none of them published in a journal. The most detailed account is in Ganeden Biotech's patent WO2013130829A1: a cream tested on 24 women aged 35 to 60 for 8 weeks, with skin hydration 7.13% above placebo and fine lines down 71.50% against 12.79% on placebo. Trade-press summaries of the company's other studies give different figures again, such as a 16% rise in hydration and an 11% rise in elasticity at 4 weeks. Nobody outside the company has checked any of it, and all of it describes a cream on the skin rather than anything swallowed.
Topical only: do not swallow
Bonicel is a cosmetic ingredient, not an oral supplement. It goes on the skin, and it is also formulated into a water-based intimate cream sold for feminine care. No oral form is sold, and no published study has given it to anyone by mouth, so nothing is known about what a capsule of it would do.
No published evidence
The supporting studies are supplier-run cosmetic trials, and not one of them has been published in a peer-reviewed journal. The trade claim of four clinical studies rests entirely on company reports. One independent trial did include a Bonicel-containing serum: a University of California Davis study that split 30 people across five different serums for one week, so only about six people used the Bonicel version. It measured skin bacteria rather than skin appearance, and no published report of it has appeared.
Mechanism of action
Fermentation metabolites, not a live probiotic
Bonicel is the liquid left over when BC30 finishes fermenting, containing lactic acid, bacteriocins, hydrogen peroxide and enzymes. It is applied to the skin. The organism is separated out, so this is not a live probiotic.
Skin barrier: proposed, not tested
No published study has tested how, or whether, these metabolites affect the skin barrier. The barrier explanation is a marketing rationale, not a measured finding.